© Drug Hunter Inc. 2018-2023
Home > “compound 46”
oral sel. PDE2A phosphodiesterase inhibitor
for cognition, target engagement in brain
from HTS, SBDD, and FEP claculations
J. Med. Chem., Oct. 26, 2020
Janssen Pharmaceutica NV, Beerse, BE
“compound 46” (Janssen oral selective brain-penetrant PDE2A phosphodiesterase inhibitor)
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year